Appendix 1: Selection of facilities and patients for NHSN dialysis event data quality evaluation

Selecting Facilities - Main steps:

1) Determine all of the facilities within your area that are eligible to participate in the evaluation (e.g., the Network, Region, State, or other geographically defined area).

2) Make a list that includes each eligible facility within the area represented; the order of the facilities on the list is not important. This is called the sampling frame.

3) Starting with the first facility listed in the sampling frame, assign each facility a number from 1 to *n*, with *n* representing the total number of facilities in the population. For example, if there are 88 facilities in your region, create a list as follows.

Facility name	Number assigned
ABC hemodialysis facility	1
ABE hemodialysis facility	2
AGC hemodialysis facility	3
AAC hemodialysis facility	88

Example: Sampling frame containing the population of 88 facilities (n = 88)

4) Determine the number of facilities to be selected (the facility sample size). Using the 88 facilities in the example above, a 20% sample would be $88 \times .20 = 17.6$ facilities; this would be round up to 18 to make a whole number. You need to identify 18 facilities from your sampling frame to be included in your sample.

5) Using a random number table (a series of digits, 0 to 9, arranged randomly through the rows and columns) or statistical software, select numbers at random that correspond to the facilities to be included in your random sample. Keep drawing numbers until you have reached your target number of randomly selected facilities (in the example provided this would be 18 different numbers). Skip over any repeated numbers - simply draw another number to replace it so that each number is different (and each number represents a unique facility). For example, if 14 is selected twice, keep the first 14 drawn but draw a new number to replace the second 14.

If the numbers drawn were: 17, 14, 37, 56, 02, 87, 81, 04, 31, 47, 64, 22, 76, 53, 52, 44, 48, 80, the facilities with these numbers assigned would be contacted and asked to participate. If you contact a facility and they decline to participate, return to the random number table or software used and draw another random number to identify an additional facility to contact.

Selecting Patients - Main steps:

1) Make a line list that includes all eligible patients from the facility - those who received one or more in-center hemodialysis treatment(s) during the evaluation time period (see the Implementation Guide document for content on list 1). The order of the patients on the list is not important. This is called the sampling frame.

2) Starting with the first patient on the sampling frame, assign each patient a number from 1 to *n*, with *n* representing the total number of eligible patients who received one or more in-center hemodialysis treatment(s) during the evaluation time period (i.e., the number of patients on list 1)

Patient	List 1	List 2	List 3	List 4	List 5	Number
identifier	See page 7	of the Implem	entation Guide	document for conten	t of lists 1 through 5	assigned
AAABBBBB	Y	Y	Ν	N	Y	1
CCCDDDD	Y	Ν	Ν	Ν	Ν	2
EEEFFFF	Y	Ν	Y	Ν	Ν	3
ABBGGGGG	Y	Ν	Ν	Ν	Ν	121

Example: Sampling frame containing the population of 121 eligible patients (n = 121)

3) Determine the number of patient charts to be selected (the patient sample size).

a) For patients included on lists 2, 3, 4 or 5: Include all of them in the sample.

b) For patients on list 1, but not included on lists 2 through 5: Select a random sample.

For example, among the 121 patients from above, 14 patients were included on lists 2-5, so a random sample should be selected from among the remaining 107 patients (121 - 14 = 107). A 10% sample would be 107 x .10 = 10.7 patients; this would be round up to 11 patients. The total patient sample size for this facility would be 25 patients; 14 patients from lists 2 through 5 + 11 patients randomly selected.

4) Using a random number table (a series of digits (0 to 9) arranged randomly through the rows and columns) or appropriate software, select the numbers that correspond to the patients that will be included in your sample. Skip over any numbers selected that are assigned to patients that are in lists 2 through 5, as they have already been included in your sample (step 4a). Keep drawing numbers until you have reached your target number of randomly selected unique patients (in this example, 11).

If the numbers drawn were; 2, 17, 54, 29, 97, 83, 07, 39, 41, 121, 85, the patients with these numbers assigned would be selected to undergo chart review (the random sample). The patients included on lists 2 through 5 would also undergo chart review.

Appendix 2a: Letter 1 – Introduction

<<Insert Date >> <<Facility Name>> <<Facility Street Address>> <<Facility City, State, Zip>>

Dear <<Name of Facility Manager>>:

I am writing to ask for your help in a data quality evaluation of Dialysis Event data that are reported to the Centers for Disease Control and Prevention's (CDC) National Healthcare Safety Network (NHSN). This evaluation is being conducted by <<a gency/group conducting evaluation>> to learn how NHSN Dialysis Event Surveillance data collection procedures are understood and carried out in dialysis facilities, as well as identify and address barriers to reporting complete and accurate data.

We are contacting you because your facility is among a subset of dialysis facilities within <<Network/state/area>> that are expected to have, on average, more data to review, or that are part of a random sample. To conduct the evaluation, staff from <<a gency/group conducting evaluation>> will be visiting several dialysis facilities in <<geographic area>> during <<time period month(s)/year of visits>>. These site visits include three main activities:

- 1. A standardized interview with facility staff involved in NHSN Dialysis Event data collection or reporting to evaluate surveillance practices within your facility.
- 2. A review of preselected patient medical records, including both paper charts and any electronic records, to assess the completeness and accuracy of the data reported to NHSN.
- 3. Education for facility staff about Dialysis Event surveillance, use of the NHSN system, and common reporting omissions and errors and their causes.

It is anticipated the visit will be completed within one day, and that the staff interview will take no longer than one hour. On the day of the visit, << agency/group conducting validation>> staff will need a space to review patient charts and access the facility's electronic medical records systems.

Evaluation of the data is critical to ensure they are complete and accurate. The findings from this evaluation will be used to identify, correct, and prevent common reporting errors. Your participation is vital to these surveillance support and data quality improvement efforts.

This evaluation is not related to any regulatory surveys; no observations will be made of infection control practices or other aspects of patient care during the site visit. The identities of participating facilities will remain confidential, and all patient identifiable information will be maintained securely and remain confidential. All visits will be scheduled – no unannounced visits will occur.

In return for your facility's participation, you will have opportunities to get confidential feedback about your facility's NHSN reporting, interact one-on-one with an NHSN Dialysis Event Surveillance expert who can address any questions you may have about reporting, and provide feedback about your experience with Dialysis Event data collection and reporting that will be used to help inform changes that will improve future reporting efforts.

Please confirm your interest in participation by contacting me with available dates for a site visit during the months of <<*site visit time period>>*. Once you confirm your participation, we will schedule a mutually agreeable date for the site visit and ask you to prepare some information on the patients who received hemodialysis treatment during <<*evaluation period>>*.

I am happy to answer any questions you have or provide further information. I can be reached at <<phone>> or via email at <<email address>>.

Thank you for your assistance to evaluate and improve the quality of NHSN Dialysis Event Surveillance data and reporting.

Sincerely,

Agency/Contact Information

Appendix 2b: Letter 2—Confirm Site Visit and Preparation

<<Insert Date >>

<<Facility Name>> <<Facility Street Address>> <<Facility City, State, Zip>>

Dear <<Name of Facility Manager>>:

Thank you again for agreeing to participate in our evaluation of NHSN Dialysis Event data and reporting. Without your participation, this valuable project would not be possible.

As discussed, we will be visiting your facility on <<*date of visit>>*. <<*Names of persons who will be conducting validation>>* from <<*name of agency>>* will arrive at approximately <*<time of arrival>>*.

Preparation before the site visit

To prepare for the chart reviews, we need you to provide the five lists of patients outlined below. Each list should include a patient medical record number, date of birth, and gender. Please send these lists to the attention of *<<Name>>* via fax at *<<number>>* by *<<deadline date>>*.

- 1. All patients who had one or more <u>in-center hemodialysis treatment(s)</u> between << month year to month year the evaluation timeframe>>.
- 2. All patients who had <u>any positive blood cultures</u> between <<*month year to month year the evaluation timeframe>>*.
- 3. All patients who received <u>any intravenous antimicrobials</u> in <<*month year to month year the evaluation timeframe>>*.
- 4. All patients who were <u>hospitalized</u> for any reason during *<<month year to month year the evaluation timeframe>>*.
- 5. All patients who had <u>any pus, redness or swelling at the vascular access site</u> during << month year to month year the evaluation timeframe>>.

These lists will be maintained securely by us to protect the release of any patient identifiers. Using the lists provided, we will preselect patient charts for us to review during the site visit. The list of patient charts for review will be provided to you in advance of the site visit.

What to expect during the site visit

When we arrive, we will need assistance to obtain the preselected patient charts. For the chart review, we will require a workspace and access to your electronic medical record system(s). You do not need to stay with us during our review, but we may need your assistance to answer intermittent questions throughout the day. When it is most convenient for you, we will interview the facility staff involved in NHSN data collection or entry, which takes about 45 minutes. The group interview is interactive and provides on-the-spot feedback about

NHSN surveillance practices and is a valuable learning opportunity for staff. Before we conclude, we will summarize our findings and review them with you, as well as address any outstanding questions from you or your staff.

Please confirm your receipt of this information, and contact me if you have any questions about preparing the lists or the site visit itself.

Thank you,

<<Primary Contact's Name>> <<Primary Contact's Title>> <<Agency/Group's Contact Information>>

Appendix 2c: Letter 3 – Post-Site Visit Summary

<<Insert Date >> <<Facility Name>> <<Facility Street Address>> <<Facility City, State, Zip>> Date of site visit: ____/____/_____/

Dear <<Name of Facility Manager>>:

Thank you for participating in the evaluation of facility surveillance practices and the Dialysis Event data reported to the National Healthcare Safety Network (NHSN). We appreciate you taking time from your schedule to work with us. The valuable information you provided will enable us to improve the quality of the data reported to NHSN, and identify focus areas for education and training of NHSN users.

During our visit, <<number>> patient charts were reviewed. The documentation from these charts was used to identify Dialysis Events that should have been reported to NHSN. Here is a summary of our findings, by event type:

IV antimicrobial starts:

- <<Number>> of IV antimicrobial start events found in charts by our staff
 - <<Number>> of these events found in charts that were reported to NHSN
 - o <<Number>> of these events found in charts that were not reported to NHSN
 - <<Number>> of these events reported to NHSN, but were not found in charts

Positive blood cultures:

- <<Number>> of positive blood culture events found in charts by our staff
 - <<*Number>>* of these events found in charts that were reported to NHSN
 - o <<Number>> of these events found in charts that were not reported to NHSN
 - o <<Number>> of these events reported to NHSN, but were not found in charts

Pus, redness, or increased swelling at the vascular access site:

- <<Number>> of pus, redness, or increased swelling events found in charts by our staff
 - o <<Number>> of these events found in charts that were reported to NHSN
 - o <<Number>> of these events found in charts that were not reported to NHSN
 - o <<Number>> of these events reported to NHSN, but were not found in charts

A summary of our findings can be found in the table below with additional details. **We would like you** to perform the following steps to correct data discrepancies that were identified:

- 1. Report to NHSN the events listed below as "under-reported". These are events that were not reported to NHSN by your facility staff, but should have been.
- 2. Delete or edit the NHSN records of the events listed below as "over-reported". These are events that were reported to NHSN by your facility staff, but should not have been.

Please make these corrections by <<*deadline>>*. Please contact us with any questions or concerns you have about making these changes.

Denominators for Outpatient Dialysis Form

From the information obtained during the interview, it appears the monthly denominator data/patient census data <<*is/is not>>* being reported correctly on the Denominators for Outpatient Dialysis form. Please <<*begin/continue>>* to report using the <u>NHSN Dialysis Event Protocol</u> instructions: "Report Denominator Data Monthly".

In addition, it is recommended that you and your staff involved in reporting review the <u>NHSN Dialysis Event</u> <u>Protocol</u>, noting the following common reporting issues found at your facility:

- <<Highlight up to 3 main issues that were discovered during the validation process. Include excerpt(s) of the <u>NHSN Dialysis Event Protocol</u> that pertain to those issues.>>
- <<l><<lssue 2>>
- <<l><<lssue 3>>

Thank you for work with regards to improving the quality of NHSN Dialysis Event surveillance data; we recognize the time and effort that you have committed. We also appreciate your willingness to participate in these important quality improvement activities. We hope the experience was also helpful to you. Please don't hesitate to contact us with any remaining questions or concerns you may have.

Sincerely,

<<Primary Contact's Name>> <<Primary Contact's Title>> <<Agency/Group's Contact Information>>

Summary Findings from Evaluation of NHSN Dialysis Event Reporting between _	//	/ and/	_/ (Page of)
---	----	--------	-------------	---

Facility N	lame:			# Patient Charts Revi	ewed:		Date of	Site Visit://
DE = Dialy								
Dialysis Ev	vent Ty	pe: PBC	C = Positive Blood Culture, AMX = I	V Antimicrobial Start, PRS = Pus, Re	dness, Swellir	ng at the Vascu	lar Access Sit	e
Vascular /	Access [·]	Types:	F = Fistula, G = Graft, T = Tunneled	Central Line, NT = Nontunneled Cer	ntral Line, O =	Other		
	DE		If yes, list the following information:					
Pat ID	iden	tified			This DE was determined to be			
FaliD			Identified during evaluation	Reported to NHSN by facility	Correctly	Under	Over	Comments/notes
	No	Yes	site visit	staff	reported	reported	reported	

Appendix 3: Survey to Evaluate NHSN Dialysis Event Surveillance Practices

INTERVIEWER INSTRUCTIONS

Prior to interview:

Identify the primary person who does NHSN Dialysis Event data collection at the facility to interview. If other staff perform NHSN activities such as data entry or analysis, it is ideal for them to also be included.

During Interview:

This interview is a tool to evaluate and improve NHSN Dialysis Event data collection and reporting. If data collection or reporting errors are identified through this evaluation of practices, the interviewer should provide education and information to help correct errors and ensure that staff report data correctly to NHSN. Refer to the *"Note to*"

Interviewer" boxes for reference information. If there is a correct answer to a question, the correct answer is **bolded**.

Note to Interviewer -

SECTION A: FACILITY INFORMATION AND NHSN

 Facility Name:
 ______NHSN Org ID:
 _____Number stations/chairs______

Interviewer Name: ______ Interview Date: ______

 Is any Dialysis Event data collected or reported by persons that do not work directly within this facility (for example, a regional or corporate employee) No Yes

a. If yes, specify who and what data:______

2. Please list all staff involved in NHSN Dialysis Event Surveillance and their involvement:

	Intervie	ewee 1	Interviewee 2		Intervie	wee 3
Name(s)						
Job Title(s)						
Background/Degree(s)						
Collects NHSN dialysis event data?	Yes	No	Yes	No	Yes	No
Collects NHSN dialysis denominator data?	Yes	No	Yes	No	Yes	No
Has access to NHSN?	Yes	No	Yes	No	Yes	No
Does NHSN data entry?	Yes	No	Yes	No	Yes	No
Creates reports/uses NHSN analysis?	Yes	No	Yes	No	Yes	No
Has read the NHSN Dialysis Event Protocol?	Yes	No	Yes	No	Yes	No
Has completed NHSN Dialysis Event Surveillance reporting training?	Yes	No	Yes	No	Yes	No

3. For staff that completed NHSN Dialysis Event Reporting Training, what kind of training did they do?

(Check all that apply)

- Online NHSN Dialysis Event Surveillance Protocol training
- □ In person, presented by a CDC trainer
- □ Webinar, presented by a CDC trainer
- □ In person, by a non-CDC trainer (e.g., ESRD Network, State Health Dept.)
- □ Webinar, by a non-CDC trainer (e.g., ESRD Network, State Health Dept.)
- Other, specify: ______
- 4. What do you (would you) do if you have a question about how or what to report to NHSN? *(Check all that apply)*
 - □ Read the NHSN Dialysis Event Protocol
 - □ Visit the NHSN Dialysis Event website (<u>http://www.cdc.gov/nhsn/dialysis/dialysis-event.html</u>)
 - □ Send an e-mail to the NHSN Helpdesk (<u>nhsn@cdc.gov</u>)
 - □ Contact the ESRD Network
 - Contact Corporate
 - □ Contact State Health Department
 - Other, specify: ______
- 5. Once data are reported to NHSN, does anyone from your facility go back and review the reported data to make sure it is correct? Yes No
 - a. If yes, specify who: ______
- 6. Within the NHSN application, have you ever generated any of the reports (also called "output options") using the analysis function? Yes No
 - a. If yes, which ones? _____
 - b. If yes, what are the reports used for? (Check all that apply)
 - □ Checking reported data are correct
 - □ Shared at quality improvement meetings
 - □ Communicating to leadership about event rates
 - □ Communicating to frontline staff about event rates
 - □ Root cause analysis of infections
 - □ Informing prevention activities
 - Other, specify: _____

SECTION B: DENOMINATOR DATA COLLECTION

7.	In your facility, which days of the month are used to count patients to obtain the monthly census data?	y denor	ninator data/patient
	The first 2 working days of the month	Yes	No
	If no, specify which days are used:	_	
8.	Are patients ever counted twice in monthly denominator data?	Yes	No
9.	Outpatient Dialysis" form? (Check all that apply)	<u>tors fo</u> i	1
	 From a computer generated report What data source is used for determining the number of patients present a access type(s) 	nd thei	r vascular

_

By performing patient chart reviews
By observation and counting of patient's vascular access types
Other method use, specify:

10. Has the method used at your facility for the monthly denominator/patient census data ever been checked to identify errors? Yes No

SECTION C: VASCULAR ACCESS

11. Do you follow the NHSN Dialysis Event definitions for vascular access types?

,				
a.	Nontunneled central line	Yes	No	N/A
b.	Tunneled central line	Yes	No	N/A
c.	Graft	Yes	No	N/A
d.	Fistula	Yes	No	N/A
e.	Other access device	Yes	No	N/A

Note to Interviewer – NHSN Surveillance Vascular Access Definitions:

Mark N/A only if the interviewee indicates they do not have or have not seen patients with that access type

- <u>Nontunneled central line</u>: a central venous catheter that travels directly from the skin entry site to a vein and terminates close to the heart or one of the great vessels, typically intended for short term use.
- <u>Tunneled central line</u>: a central venous catheter that travels a distance under the skin from the point of insertion before terminating at or close to the heart or one of the great vessels (e.g., Hickman[®] or Broviac[®] catheters).
- <u>Graft:</u> a surgically created connection between an artery and a vein using implanted material (typically synthetic tubing) to provide a permanent vascular access for hemodialysis.
- <u>Fistula</u>: a surgically created direct connection between an artery and a vein to provide vascular access for hemodialysis.
- <u>Other access device</u>: includes hybrid access devices (e.g., HeRO[®] vascular access device), ports, and any other central vascular access devices not meeting the above definitions.

Use of trade names and commercial sources is for identification only and does not imply endorsement.

HIGHER	Nontunneled Central	Tunneled Central	Other Access	AV	AV	LOWER
RISK	Lines	Lines	Devices	Grafts	Fistulas	RISK

12. When determining in which vascular access category to count a patient for the monthly denominators:

a. Do you consider vascular accesses <u>not presently in use</u> (e.g., a tunneled central line **Yes** No that is retained as a back-up while a new fistula is tested for patency) to determine the appropriate category?

b. Do you consider vascular accesses that are <u>not used for dialysis</u> (e.g., chemotherapy **Yes** No ports) to determine the appropriate category?

c. Do you consider <u>abandoned vascular accesses</u> (e.g., clotted AV fistulas) to determine **Yes** No the appropriate category?

d. How are patients with <u>more than one access type categorized</u>? Specify:

13. When counting denominator data, which of the following patients are included?

a.	Hospitalized patients	Yes	No
b.	Patients who missed their scheduled treatment	Yes	No
с.	Transient patients	Yes	No

<u>Note to Interviewer</u> – Protocol instructions for dialysis denominator data collection:

Each month, report the number of maintenance hemodialysis patients with each vascular access type who received hemodialysis at the center during the first two working days of the month on the Denominators for Outpatient Dialysis form. Report all maintenance hemodialysis outpatients, including transient patients. Exclude non-hemodialysis patients and exclude inpatients. Report denominator data each month, regardless of whether any dialysis events occur. Each patient is counted only once; if the patient has multiple vascular accesses, record that patient once, reporting their highest infection risk vascular access type only. See tables of instructions for an explanation of each field on the Denominators for Outpatient Dialysis form.

14. If not using NHSN denominator criteria, summarize below how denominator is determined at this facility:

SECTION D: DIALYSIS EVENTS

15. What are the three types of "dialysis events" monitored for NHSN Dialysis Event surveillance?

	Identified	Not identified
IV antimicrobial starts		
Positive blood cultures		
Pus, redness, or increased swelling at the vascular access site		

Note to Interviewer – Protocol definitions for dialysis events:

- <u>IV antimicrobial start:</u> Report **all** outpatient intravenous (IV) antibiotic and antifungal starts, regardless of the reason for treatment (i.e., include IV antimicrobial starts unrelated to vascular access problems) and regardless of the duration of treatment. Report all IV antibiotic starts, not just vancomycin. Do **not** report IV antiviral starts. Report outpatient starts that are continuations of inpatient treatment.
- <u>Positive blood culture:</u> Report **all** positive blood cultures collected as an outpatient or collected within 1 calendar day after a hospital admission, regardless of whether or not the patient received treatment.
- <u>Pus, redness, or increased swelling at the vascular access site</u>: Report **each** new outpatient episode where the patient has one or more symptoms of pus, greater than expected redness or greater than expected swelling at a vascular access site, regardless of whether the patient received treatment.

See next page for the application of the 21 day rule for each event type.

16. Do you check to see if the "21 day rule" applies, before reporting a new dialysis event?

- □ Yes, the 21 day rule is checked
- □ No, the 21 rule is not checked
- □ No, not aware of the 21 day rule

17. If <u>yes</u> , please describe how you apply the rule:	Correctly d	lescribed?
a. For IV antimicrobial starts:	Yes	No
b. For Positive blood cultures:	Yes	No
c. For Pus, redness, or increased swelling at the vascular access site:	Yes	No
d. When applying the 21 day rule, do you look back to the preceding	Yes	No

month for events (instead of checking only within the current month)?

<u>Note to Interviewer</u> – 21 Day Rule applies only within the same dialysis event types:

If a patient has two dialysis events <u>of the same type</u>, the second occurrence is reported only if there are 21 or more days between the events. If the second event falls exactly on the 21st day, it is reported.

<u>IV antimicrobial starts</u>: There must be 21 or more days from the **end** of one IV antimicrobial course to the **beginning** of a second IV antimicrobial dose or course in an outpatient setting for two starts to be reported as separate dialysis events, even if different antimicrobials are used

<u>Positive blood cultures</u>: There must be 21 or more days between positive blood cultures for each positive blood culture to be considered a separate dialysis event, even if organisms are different

Pus, redness, or increased swelling: count days between onset to onset.

There must be 21 or more days between the **onset** of a first episode and the **onset** of a second episode of pus, redness, or increased swelling at a vascular access site to be considered separate dialysis events

Examples:

<u>21 day rule for IV antimicrobial starts:</u> a single dose of IV cefazolin is administered in the dialysis facility prophylactically prior to AV graft placement surgery. Within two weeks, patient shows signs of bloodstream infection and is started empirically on IV vancomycin. Report only one dialysis event for the IV cefazolin; the IV vancomycin was started within 21 days of the prophylactic dose and is therefore, not reported.

<u>21 day rule for positive blood cultures:</u> patient has a positive blood culture on January 1, 22, and 24. Report two dialysis events: one for January 1 and one for January 22. The positive blood culture from January 24 is <u>not</u> reported because there are fewer than 21 days between January 22 and 24.

<u>21 day rule for pus, redness, or increased swelling at the vascular access site</u>: Patient's tunneled central line exit site is slightly red on January 1. Over the course of four days, the redness worsens, and the vascular access site becomes warm to the touch, and tender. Patient receives a 10 day course of oral antibiotics and the symptoms resolve. On January 19, the redness returns. Report one dialysis event: the second onset of redness on January 19 is within 21 days of the first onset of redness on January 1 and is therefore not reported.

18. How are Dialysis Events identified and tracked for NHSN surveillance at your facility?

<u>Note to interviewer:</u> Ask about the different sources of data that are used to find each type of dialysis event, and the process that is used to ensure all information is captured and reported correctly. Prompt the interviewee with examples as necessary. Use the table below to summarize the responses by checking the box if the interviewee indicated they used that data source or process.

	T	ype of Dialysis Eve	nt
	IV antimicrobial start	Positive blood culture	Pus, redness, or increased swelling
What data sources do you use to help you fi	nd Dialysis Events?		·
Daily direct observation of patients			
Patient chart reviews			
Review computer generated reports			
If used computer reports, specify the type(s):			
Staff discussion			
Pharmacy records			
Positive laboratory reports			
Hospitalization records			
Patient temperature records			
Administrative (billing or discharge) codes			
Other data sources, specify:			
How frequently is case finding done (e.g., daily, weekly, monthly, quarterly)?			
Once you have identified a patient with a Di them before they are entered into NHSN?	alysis Event, what	process do you use	to keep track of
Keep a line listing (e.g., a log) of events			
Fill out a paper NHSN Dialysis Event form			
Flag events in Electronic Medical Record			
Other, specify:			

19. Does y	our facility keep track of all patient hospitalizations?	Yes	No
•	tients routinely asked the following at each treatment visit: Do you have any signs or symptoms of infection?	Yes	No
	Have you had any ED visits or hospitalization since the last treatment?	Yes	No
c.	If no to b, what process is used to find out if a patient had an ED visit or was h	ospitalized	l between
	treatments?		

21. /	After p	atients retur	n to your facility following a hospitalization, does your facility request a	сору	of
Ŋ	your di	alysis patien	ts' medical records?	Yes	No
	a.	Are hospita	I records requested for every hospitalization?	Yes	No
	b.	Is there a st	tandard process to request hospital records (e.g., a request form)?	Yes	No
	с.	Does your f	acility have a follow-up system in place to ensure all requested records	are	
		received?		Yes	No
	d.	Please spec	ify the type of records requested for all patient hospitalizations:		
		(Check	all that apply)		
			Admission history and physical		
			Microbiology laboratory reports		
			Pharmacy/drug administration records/logs		
			Discharge summary		
			The complete hospitalization record		
			Other, specify:		
22. I	Does yo	our facility h	ave a process in place to identify and report positive blood cultures coll	ected	
(during	the first dav	of a dialysis patient's hospital admission?	Yes	No

- a. If yes, please describe the process:
- 23. If new dialysis event information is identified after the event has already been reported, do you go back and revise the record? Yes No

<u>Note to Interviewer</u> – revising reported data:

On occasion, data reported to NHSN may need to be updated with new information and/or corrected if errors are identified. It is expected that the information will be revised in these instances.

Example: A patient has a positive blood culture in January. This dialysis event is reported to NHSN in February. The patient dies in March as a result of the bloodstream infection. The record should be accessed in March and edited to modify "Outcome: Death" to "Yes".

SECTION E: ADDITIONAL QUESTIONS TO IDENTIFY AREAS OF NHSN IMPROVEMENT

24.	24. What 2 things would be most helpful to improve NHSN data collect	tion and/or reporting?
	a	
	b	
25.	25. What are the 2 main challenges to NHSN reporting?	
	a	
	b	
26.	26. Do you have any other questions or comments about NHSN?	

Appendix 4: NHSN Dialysis Event Surveillance: Chart Review Form

Instructions: The attached form is a tool to review a hemodialysis outpatient chart and collect NHSN Dialysis Event Surveillance information to determine whether data were correctly reported. Chart reviewers must be familiar with the NHSN Dialysis Event Protocol instructions and definitions prior to chart review.

First complete sections A and B, for section C, note all (1) IV antimicrobial starts; (2) positive blood cultures; and instances of (3) pus, redness, or increased swelling at the vascular access site, identified for this patient, as defined by the NHSN Dialysis Event Protocol. Arrange events of the <u>same</u> type chronologically. Use the calendar on page 4 to help you apply the 21 day rule to determine which events should have been reported to NHSN. For section D, summarize the events that <u>should have been reported</u> during the evaluation time period, ensuring that the event type, the event date, and the access type(s) are all correct.

Legend:						
Category	Abbreviation	Name		Summary of the 21 Day Rule		
	PBC	Positive blood culture		21 Day Rule: There must be 21 or more days		
Dialveic	AMX	IV antimicrobial start		between two events of the <u>same type</u> for the second		
Dialysis Events	PRS	Pus, redness, or increased swelling of the vascular a site		event to be reported. IV antimicrobial start: From the <u>end</u> of one course		
	VA	Vascular access site		to <u>beginning</u> of the next (i.e., only IV antimicrobials		
Suspected Sources	0	Source other than the vas access site	scular	restarted on or after the 21 st day following the end of a previous dose/course are reported)		
Sources	С	Contamination				
	U	Uncertain		Positive blood cultures: Between blood specimen		
	F	Fistula		collection dates (i.e., only positive blood cultures		
	G	Graft		collected on or after the 21 st day following the last		
Vascular	Т	Tunneled central line		collected positive blood culture are reported)		
Accesses	NT	Nontunneled central line				
	0	Other access device		Pus, redness, or increased swelling: Between onset		
	Y	Yes		to onset (i.e., only new onset on or after the 21 st day		
Result	N	No		following the previous onset is reported)		
	U	Unknown				
		Common NHSN Dia	lysis Eve	ent Reporting Errors		
whetherone caleIncorrecover-repEvent Date	positive blood cu ndar day after ho t application of 22 orting	spitalizations to identify Itures were obtained within spital admission L day rule often results in date among >1 related	 IV antimicrobial start: Failure to report if: A one-time or prophylactic dose is given Related blood culture results are negative Treatment is for non-vascular access problems (e.g., pneumonia) It is the first outpatient IV antimicrobial administration resulting from continuation of inpatient treatment Administered on outpatient basis, <u>outside</u> of the dialysis facility (e.g., in nursing home, prison) 			
 Result is IV antim Attribute wound in 	icrobials are not s ed to non-vascula nfection, pneumo d within first day	ue to contamination started r access problems (e.g.,	• An • Inf	dness, or increased swelling: Failure to report if: timicrobials are not started fection is suspected but not confirmed ck process to track these events		

30

Section A: Facility and patient information												
Facility name			Patient Name									
NHSN Org ID			Med record number									
Reviewer name			NHSN Patient ID									
Review date			Date of birth									
Evaluation	From:	(month/year)	Gender	Male / Female								
time period	То:	(month/year)	Transient Patient	Yes / No								

Section B: Record the vascular access types identified during the validation time period. Include all vascular accesses present,												
even if it was not	being used for	dialysis										
Access(es)	Present	If present, placement date(s)	Discontinued date(s)									
Fistula												
Graft												
Tunneled												
Nontunneled												
Other Access												
If placement or di	iscontinuation d	ates are not documented, please write "unknow	wn"									

Start date	End date	Drug name	Problems documented*	Should this event reported to NHS	
				Y N	Y N
				Y N	Y N
				Y N	Y N
				Y N	Y N
				Y N	Y N
				Y N	Y N
				Y N	Y N
				Y N	Y N
				Y N	Y N
				Y N	Y N
				Y N	Y N
				Y N	Y N
				Y N	Y N
				Y N	Y N
				Y N	Y N

Section C: PBC - All positive blood cultures

BC Draw Date	Pathogen(s)	Suspected Source	Problems documented*	Should this event be reported to NHSN?	Was this event reported to NHSN by facility?		
		VA O C U		Y N	Y N		
		VA O C U		Y N	Y N		
		VA O C U		Y N	Y N		
		VA O C U		Y N	Y N		
		VA O C U		Y N	Y N		
		VA O C U		Y N	Y N		
		VA O C U		Y N	Y N		
		VA O C U		Y N	Y N		
		VA O C U		Y N	Y N		
		VA O C U		Y N	Y N		

*Problems include: Fever, chills/rigors, drop in blood pressure, wound infection, cellulitis, pneumonia, other, or none Notes:

Section C: PRS - All pus, redness, or increased swelling at the vascular access site

L Chart rev	lew for this pa	tient completed and	no PRS found during	the evaluation time period			
PRS Onset Date	Pus, Redness, Swelling^	Vascular Access(es) Affected	Problems documented*	Should this event be reported to NHSN?	Was this event reported to NHSN by facility?		
	PRS	FGTNTO		Yes No	Y N		
	PRS	FGTNTO		Yes No	Y N		
	PRS	FGTNTO		Yes No	Y N		
	PRS	FGTNTO		Yes No	Y N		
	PRS	FGTNTO		Yes No	Y N		
	PRS	FGTNTO		Yes No	Y N		
	PRS	FGTNTO		Yes No	Y N		
	PRS	FGTNTO		Yes No	Y N		
	PRS	FGTNTO		Yes No	Y N		
	PRS	FGTNTO		Yes No	Y N		

[^]Other terms that may be used to document PRS *may* include: For PUS: purulent, excretion, secretion, discharge, seepage, ooze, suppuration. For REDNESS: cellulitis, inflamed, ruddy, rosy. For SWELLING: distended, puffy, tumescent, tumid, edema

*Problems include: Fever, chills/rigors, drop in blood pressure, wound infection, cellulitis, pneumonia, other, or none Notes:

	J	lar	านส	ary	y			F	eb	ru	ar	У				M	aro	ch		
Su	Мо	Tu	We	Th	Fr	Sa	Su	Мо	Tu	We	Th	Fr	Sa	Su	Мо	Tu	We	Th	Fr	Sa
		1	2	3	4	5						1	2						1	2
6	7	8	9	10	11	12	3	4	5	6	7	8	9	3	4	5	6	7	8	9
13	14	15	16	17	18	19	10	11	12	13	14	15	16	10	11	12	13	14	15	16
20	21	22	23	24	25	26	17	18	19	20	21	22	23	17	18	19	20	21	22	23
27	28	29	30	31			24	25	26	27	28			24	25	26	27	28	29	30
														31						
		Α	pr	il					Ν	/la	У			June						
Su	Мо	Tu	We	Th	Fr	Sa	Su	Мо	Tu	We	Th	Fr	Sa	Su	Мо	Tu	We	Th	Fr	Sa
	1	2	3	4	5	6				1	2	3	4							1
7	8	9	10	11	12	13	5	6	7	8	9	10	11	2	3	4	5	6	7	8
14	15	16	17	18	19	20	12	13	14	15	16	17	18	9	10	11	12	13	14	15
21	22	23	24	25	26	27	19	20	21	22	23	24	25	16	17	18	19	20	21	22
								27	28	00		04		0.0	24	25	24	27	28	29
28	29	30					26	27	28	29	30	31		23	24	20	26	27	20	29
28	29	30					26	27	28	29	30	31		23 30	24	20	26	21	20	29
28	29		ul	y			26			Igu				30			en			
		J	ul <u>y</u> We		Fr	Sa			Au		ıst		Sa	30	Se	ept		nb	er	
		J			Fr 5	Sa 6			Au	ıgı	ıst		Sa 3	30	Se	ept	en	nb	er	
	Мо	J Tu	We	Th					Au	ıgı	ist Th	Fr		30 Su	Se Mo	e pt Tu	en We	nb Th	er Fr	Sa

Calendar for year: 2013 [Insert calendar corresponding to your evaluation time period]

October							November						December							
Su	Мо	Tu	We	Th	Fr	Sa	Su	Мо	Tu	We	Th	Fr	Sa	Su	Мо	Tu	We	Th	Fr	Sa
		1	2	3	4	5						1	2	1	2	3	4	5	6	7
6	7	8	9	10	11	12	3	4	5	6	7	8	9	8	9	10	11	12	13	14
13	14	15	16	17	18	19	10	11	12	13	14	15	16	15	16	17	18	19	20	21
20	21	22	23	24	25	26	17	18	19	20	21	22	23	22	23	24	25	26	27	28
27	28	29	30	31			24	25	26	27	28	29	30	29	30	31				

25 26 27 28 29 30 31

22 23 24 25 26 27 28

29 30

21 22 23 24 25 26 27 18 19 20 21 22 23 24

28 29 30 31

Section D: Summary of Dialysis Events identified for this patientPatient Name/MRN:Chart review for this patient completed and no Dialysis Events were found during the evaluation time period

1.	Dialysis	Event Summary Form	Was this event reported to			
Ever	vent Date: Access type(s) present for this event date:			NHSN by the facility? Y N		
	AMX	Vancomycin: Yes No				
	PBC	Suspected Source: Vascular Access Other Source Contamination	Uncertain			
		Pathogen(s):				
	PRS	Access(es): Fistula Graft Tunneled Central Line Nontunneled Cen	itral Line	Other Access Device		
Problems, notes:						

2.	Dialysis	Event Summary Form	Was this event reported to			
Evei	nt Date:	Access type(s) present for this event date:	NHSN by the facility? Y N			
	AMX	Vancomycin: Yes No				
	PBC	Suspected Source: Vascular Access Other Source Contamination Un Pathogen(s) :	ncertain			
	PRS	Access(es): Fistula Graft Tunneled Central Line Nontunneled Centra	al Line Other Access Device			
Problems, notes:						

3. Dialysis Event Summary Form							Was this event reported to		
Event Date: Ac		cess ty	ess type(s) present for this event date:				NHSN by the facility? Y N		
	AMX	Vancomycin:	Yes N	0					
	PBC	Suspected Sour Pathogen(s) :	rce: \	Vascular /	Access	Other Source	Contamination	Uncertain	
	PRS	Access(es): F	istula	Graft	Tunne	led Central Line	Nontunneled Ce	ntral Line	Other Access Device
Prob	lems, no	tes:							

4.	Dialysis	Event Summary Form	Was this	Was this event reported to	
Ever	Event Date: Access type(s) present for this event date:			NHSN by the facility? Y N	
	AMX	Vancomycin: Yes No			
	PBC	Suspected Source: Vascular Access Other Source Contamination Pathogen(s) :	n Uncertain	1	
	PRS	Access(es): Fistula Graft Tunneled Central Line Nontunneled	Central Line	Other Access Device	
Prob	olems, not	tes:			